LON:IBT - International Biotechnology Trust Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 672 +665.47 (+10,190.96 %)
(As of 09/21/2018 04:00 PM ET)
Previous CloseGBX 672
Today's RangeGBX 657.16 - GBX 672
52-Week RangeGBX 552 - GBX 650
Volume43,088 shs
Average Volume37,914 shs
Market Capitalization£220.09 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
International Biotechnology Trust logoInternational Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of these companies to strategic buyers including major pharmaceutical companies or, in some cases, and through a flotation.

Receive IBT News and Ratings via Email

Sign-up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange LON
Industry Asset Management
Sub-IndustryN/A
SectorFinancial Services
SymbolLON:IBT
CUSIPN/A
PhoneN/A

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins91.83%
Return on Equity8.30%
Return on Assets7.65%

Miscellaneous

EmployeesN/A
Outstanding Shares37,550,000
Market Cap£220.09 million

International Biotechnology Trust (LON:IBT) Frequently Asked Questions

What is International Biotechnology Trust's stock symbol?

International Biotechnology Trust trades on the London Stock Exchange (LON) under the ticker symbol "IBT."

How often does International Biotechnology Trust pay dividends? What is the dividend yield for International Biotechnology Trust?

International Biotechnology Trust declared a dividend on Wednesday, July 11th. Shareholders of record on Thursday, August 2nd will be given a dividend of GBX 13.50 per share on Friday, August 31st. This represents a yield of 2.05%. The ex-dividend date of this dividend is Thursday, August 2nd. The official announcement can be seen at this link. View International Biotechnology Trust's Dividend History.

Who are some of International Biotechnology Trust's key competitors?

Who are International Biotechnology Trust's key executives?

International Biotechnology Trust's management team includes the folowing people:
  • Ms. Lucy Cost Duarte, Head of Investor Relations
  • Ms. Kate Bingham, Managing Partner
  • Ms. Ailsa Craig, Investment Mang.
  • Dr. Carl Harald Janson, Lead Investment Mang.

How do I buy shares of International Biotechnology Trust?

Shares of IBT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is International Biotechnology Trust's stock price today?

One share of IBT stock can currently be purchased for approximately GBX 672.

How big of a company is International Biotechnology Trust?

International Biotechnology Trust has a market capitalization of £220.09 million.

What is International Biotechnology Trust's official website?

The official website for International Biotechnology Trust is http://www.ibtplc.com/.


MarketBeat Community Rating for International Biotechnology Trust (LON IBT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  61 (Vote Underperform)
Total Votes:  181
MarketBeat's community ratings are surveys of what our community members think about International Biotechnology Trust and other stocks. Vote "Outperform" if you believe IBT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IBT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2018 by MarketBeat.com Staff

Featured Article: Trading Penny Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel